Rapid Transition to Buprenorphine in a Patient With Methadone-Related QTc Interval Prolongation
- PMID: 34864786
- DOI: 10.1097/ADM.0000000000000935
Rapid Transition to Buprenorphine in a Patient With Methadone-Related QTc Interval Prolongation
Abstract
Background: Patients with opioid use disorder (OUD) who are managed on methadone often require transition to buprenorphine therapy. Current recommendations require months to gradually taper off of methadone; however, in some cases, the need to transition is urgent. Only a few rapid methadone-to-buprenorphine transitions have been reported and there are no established protocols to guide clinicians in these cases.
Case presentation: A 43-year-old man on 95 mg methadone for opioid use disorder experienced cardiac arrest attributable to ventricular fibrillation caused by QTc interval prolongation from methadone. In the hospital, a gradual taper of methadone was initiated but proved intolerable; the patient requested to restart his home dose of methadone and leave against medical advice. A rapid transition was initiated instead. Naltrexone (25 mg) was used to precipitate acute withdrawal followed 1 hour later by a "rescue" with buprenorphine/naloxone (16 mg/4 mg). The Clinical Opiate Withdrawal Score (COWS) peaked at 21 post-naltrexone and fell quickly to 15 within a half-hour of buprenorphine/naloxone administration. The patient was maintained on a total daily dose of 16 mg/4 mg buprenorphine/naloxone through the time of discharge.
Conclusions: A patient requiring an urgent taper off of methadone due to adverse cardiac effects successfully transitioned to buprenorphine/naloxone within 2 hours by using naltrexone to precipitate withdrawal followed by a "rescue" with buprenorphine/naloxone. A relatively high dose of 16 mg/4 mg buprenorphine/naloxone successfully arrested withdrawal symptoms. With further refinement, this protocol may be an important technique for urgent methadone-to-buprenorphine transitions in the inpatient setting.
Copyright © 2021 American Society of Addiction Medicine.
Conflict of interest statement
The authors report no conflicts of interest.
References
-
- Lintzeris N, Monds LA, Rivas C, et al. Transferring patients from methadone to buprenorphine: the feasibility and evaluation of practice guidelines. J Addict Med . 2018;12(3):234–240.
-
- Nosyk B, Sun H, Evans E, et al. Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study. Addiction . 2012;107(9):1621–1629.
-
- Winstock AR, Lintzeris N, Lea T. Why do patients report transferring between methadone and buprenorphine? Drug Alcohol Rev . 2009; 28(6):686–687.
-
- Lintzeris N, Mankabady B, Rojas-Fernandez C, Amick H. Strategies for transfer from methadone to buprenorphine for treatment of opioid use disorders and associated outcomes: a systematic review. J Addict Med . 2021. doi:10.1097/ADM.0000000000000855.
-
- Charney DS, Heninger GR, Kleber HD. The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone. Am J Psychiatry . 1986;143(7):831–837.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical